ライフサイエンスコーパス: implantable

1 nstructs, which are vascularized and readily implantable.

2 le medical devices is to develop mechatronic implantable artificial organs such as artificial pancrea

3 For the development of optimal mechatronic implantable artificial organs, these modules should be s

4 ity, leading to applications in transient or implantable bioelectronics and optoelectronics.

5 Current review highlights the progress on implantable biofuel cell, with focus on the nano-carbon

6 ion for a variety of applications, including implantable biofuel cells and self-powered sensors.

7 pproaches to enhance the enzyme functions in implantable biofuel cells.

8 ng selectivity and robustness as a potential implantable biomedical device.

9 Here, we have tested implantable biopolymer devices that deliver CAR T cells

10 Clinical considerations for implantable bioprinted tissues are further expounded tow

11 a wide range of applications in digital and implantable biosensors and high-throughput DNA genotypin

12 The foreign body response to implantable biosensors has been successfully countered t

13 ntroller, (2) peripheral components, and (3) implantable blood pump or its integral electric drivelin

14 However, such a technology would require an implantable BP marker, which is not available yet.

15 66 in the validation cohort, and 0.69 in the implantable cardiac defibrillator arm of the validation

16 sudden cardiac arrests (arrhythmic death or implantable cardiac defibrillator discharge for ventricu

17 hemic cardiomyopathy (n=204) eligible for an implantable cardiac defibrillator for the primary preven

18 patients with AVNA (26% of whom underwent an implantable cardiac defibrillator implant and 37% underw

19 ignant arrhythmic events such as appropriate implantable cardiac defibrillator shock (n=4), sustained

20 27 patients of group 1 experienced multiple implantable cardiac defibrillator shocks for recurrent V

21 symptomatic Brugada syndrome patients having implantable cardiac defibrillator were enrolled: 63 (gro

22 etter target patients likely to benefit from implantable cardiac defibrillators, which have no impact

23 in patients with prosthetic valves (PVs) and implantable cardiac electronic devices (ICEDs).

24 Implantable cardiac pacing and defibrillation devices ar

25 Implantable cardiac vagal nerve stimulators are a promis

26 previously showed a survival benefit of the implantable cardioverter defibrillator (ICD) in males wi

27 about the use of CRT in combination with an implantable cardioverter defibrillator (ICD) in patients

28 ecently, magnetic resonance (MR)-conditional implantable cardioverter defibrillator (ICD) systems hav

29 To our knowledge, whether implantable cardioverter defibrillator (ICD) therapy imp

30 and heterogeneity of LGE predict appropriate implantable cardioverter defibrillator (ICD) therapy in

31 wed a significant reduction in inappropriate implantable cardioverter defibrillator (ICD) therapy in

32 as among patients randomized to CRT-D versus implantable cardioverter defibrillator (ICD) were compar

33 ipt of CRT with defibrillator (CRT-D) versus implantable cardioverter defibrillator (ICD), and outcom

34 ated with early adoption of the subcutaneous implantable cardioverter defibrillator (S-ICD) in the Un

35 or ventricular fibrillation; and n=8 without implantable cardioverter defibrillator although with sym

36 , for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic

37 The implantable cardioverter defibrillator appropriate inter

38 ovariates suggested for effect modification (implantable cardioverter defibrillator at baseline, left

39 as the most important criterion to determine implantable cardioverter defibrillator candidacy.

40 eceiving a cardiac resynchronization therapy implantable cardioverter defibrillator for the treatment

41 rience a significant complication related to implantable cardioverter defibrillator implantation in c

42 of patients who are the best candidates for implantable cardioverter defibrillator implantation is o

43 d this observation require further study but implantable cardioverter defibrillator implantation shou

44 risk of nonsudden death who may benefit from implantable cardioverter defibrillator implantation.

45 ho did not have a preexisting indication for implantable cardioverter defibrillator implantation.

46 rent guidelines only recommend the use of an implantable cardioverter defibrillator in patients with

47 vice-related complications and inappropriate implantable cardioverter defibrillator interventions.

48 Implantable cardioverter defibrillator is the only prove

49 Patients with persistent AF, dual-chamber implantable cardioverter defibrillator or cardiac resync

50 alone, this results in approximately 130 000 implantable cardioverter defibrillator placements at a c

51 Medicare patients from the Implantable Cardioverter Defibrillator Registry (January

52 tation; n=6 with previous cardiac arrest and implantable cardioverter defibrillator shocks for ventri

53 ci improves symptoms and reduces appropriate implantable cardioverter defibrillator shocks.

54 ome (9 sudden cardiac arrest, 40 appropriate implantable cardioverter defibrillator therapies).

55 ion 30%) were studied (6 month preprocedural implantable cardioverter defibrillator therapies: median

56 Women are less likely to be referred for implantable cardioverter defibrillator therapy despite c

57 proportion of patients received appropriate implantable cardioverter defibrillator therapy during me

58 ation, sudden cardiac death, and appropriate implantable cardioverter defibrillator therapy was noted

59 n tool used in the selection of patients for implantable cardioverter defibrillator therapy.

60 sk of SCD may gain longevity from successful implantable cardioverter defibrillator therapy.

61 come of sudden cardiac arrest or appropriate implantable cardioverter defibrillator therapy.

62 ejection fraction 35% or less, an automatic implantable cardioverter defibrillator, and who were ine

63 ppropriate antitachycardia pacing from their implantable cardioverter defibrillator, or both.

64 ility of life-saving preventive therapy, the implantable cardioverter defibrillator.

65 icular pacemaker, and 1 has a single chamber implantable cardioverter defibrillator.

66 any duration in patients with pacemakers and implantable cardioverter defibrillators (ICDs) and evalu

67 Clinical trials of implantable cardioverter defibrillators (ICDs) for prima

68 licting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for prima

69 at high SCD risk, prophylactic insertion of implantable cardioverter defibrillators (ICDs) reduces m

70 The study group comprised 160 patients with implantable cardioverter defibrillators (ICDs), of whom

71 Women receiving implantable cardioverter defibrillators for primary prev

72 Patients were excluded if they had implantable cardioverter defibrillators or permanent pac

73 THODS AND Pigs implanted with single-chamber implantable cardioverter defibrillators to record ventri

74 Implantable cardioverter defibrillators were placed in 1

75 Danish Study to Assess the Efficacy of ICDs [Implantable Cardioverter Defibrillators] in Patients Wit

76 509 patients who had a pacemaker (58%) or an implantable cardioverter-defibrillator (42%) that was no

77 cemaker or a biventricular pacemaker with an implantable cardioverter-defibrillator (CRT-D).

78 with defibrillator (CRT-D) compared with an implantable cardioverter-defibrillator (ICD) alone are u

79 comorbidities with the benefits of CRT over implantable cardioverter-defibrillator (ICD) alone.

80 k patients eligible for a primary prevention implantable cardioverter-defibrillator (ICD) are less li

81 ave their EF reassessed 40 days after MI for implantable cardioverter-defibrillator (ICD) candidacy.

82 The subcutaneous implantable cardioverter-defibrillator (ICD) has emerged

83 SCD may be prevented by implantable cardioverter-defibrillator (ICD) implantatio

84 have found that primary prevention use of an implantable cardioverter-defibrillator (ICD) improves su

85 The benefit of an implantable cardioverter-defibrillator (ICD) in patients

86 nter trials have established the role of the implantable cardioverter-defibrillator (ICD) in the trea

87 Implantable cardioverter-defibrillator (ICD) indications

88 g survivors of myocardial infarction with an implantable cardioverter-defibrillator (ICD) is frequent

89 The implantable cardioverter-defibrillator (ICD) is the stan

90 For the former, an implantable cardioverter-defibrillator (ICD) is typicall

91 Patients with an unused or malfunctioning implantable cardioverter-defibrillator (ICD) lead may ha

92 or IIa indications for CRT-D were matched to implantable cardioverter-defibrillator (ICD) patients wi

93 ackground: Long-term nonfatal outcomes after implantable cardioverter-defibrillator (ICD) placement a

94 EF) is recommended before primary prevention implantable cardioverter-defibrillator (ICD) placement.

95 Implantable cardioverter-defibrillator (ICD) recipients

96 utaneous coronary intervention (CathPCI) and implantable cardioverter-defibrillator (ICD) registries

97 (CSD) has been shown to reduce the burden of implantable cardioverter-defibrillator (ICD) shocks in s

98 rictions for 3 to 6 months after appropriate implantable cardioverter-defibrillator (ICD) shocks, con

99 .5 tesla for patients who had a pacemaker or implantable cardioverter-defibrillator (ICD) that was "n

100 ypes of devices that include the transvenous implantable cardioverter-defibrillator (ICD) with or wit

101 y an automatic external defibrillator (AED), implantable cardioverter-defibrillator (ICD), or wearabl

102 tion ECGs would predict arrhythmic events in implantable cardioverter-defibrillator (ICD)-eligible ca

103 , would predict the survival benefit with an implantable cardioverter-defibrillator (ICD).

104 tachycardia that was induced by means of an implantable cardioverter-defibrillator (ICD).

105 CM) ECG make it a challenge for subcutaneous implantable cardioverter-defibrillator (S-ICD) screening

106 The subcutaneous implantable cardioverter-defibrillator (S-ICD) was devel

107 cantly increased risk with CRT-D relative to implantable cardioverter-defibrillator -only.

108 45% versus 56% among patients randomized to implantable cardioverter-defibrillator and CRT with defi

109 We excluded patients with prior implantable cardioverter-defibrillator and those randomi

110 Decisions about the placement of an implantable cardioverter-defibrillator are based on an e

111 with a greater increase in RWT compared with implantable cardioverter-defibrillator at 12 months (4.6

112 Patients who had an implantable cardioverter-defibrillator at the time of tr

113 Although an implantable cardioverter-defibrillator can save lives in

114 mporary treatment 18 experienced appropriate implantable cardioverter-defibrillator discharges, 2 und

115 all-cause mortality, composite end point of implantable cardioverter-defibrillator efficacy (arrhyth

116 Patients with implantable cardioverter-defibrillator explantation had

117 bined endpoint of cardiac death, appropriate implantable cardioverter-defibrillator firing, resuscita

118 erion for selecting patients with DCM for an implantable cardioverter-defibrillator for primary preve

119 hmic therapy and the life-saving role of the implantable cardioverter-defibrillator highlight the imp

120 icular arrhythmias, sudden cardiac death, or implantable cardioverter-defibrillator implantation in a

121 of DFT versus no-DFT testing at the time of implantable cardioverter-defibrillator implantation was

122 ch to the selection of patients with DCM for implantable cardioverter-defibrillator implantation.

123 may have direct impact on the indication of implantable cardioverter-defibrillator implantation.

124 the chest, nuclear procedures, and pacemaker/implantable cardioverter-defibrillator insertion and rep

125 terventions (1.0 to 2.4 per 1000), pacemaker/implantable cardioverter-defibrillator insertions (1.6 t

126 ed in 63 other high-risk patients (13%) with implantable cardioverter-defibrillator interventions for

127 ubcutaneous implantation of the subcutaneous implantable cardioverter-defibrillator may offer procedu

128 F hospitalization or death with CRT-D versus implantable cardioverter-defibrillator only therapy, whe

129 s to investigate the impact of an additional implantable cardioverter-defibrillator over CRT, accordi

130 o 26.8% (p < 0.0001); the frequency of VT in implantable cardioverter-defibrillator patients with rec

131 m the National Cardiovascular Data Registry, implantable cardioverter-defibrillator registry between

132 After implantable cardioverter-defibrillator shock, related HC

133 Radiofrequency catheter ablation reduced implantable cardioverter-defibrillator shocks and VT epi

134 recurrence; the proportion of patients with implantable cardioverter-defibrillator shocks decreased

135 rphic ventricular tachycardia requiring >/=2 implantable cardioverter-defibrillator shocks occurred i

136 Implantable cardioverter-defibrillator shocks seem to tr

137 opriate ventricular fibrillation-terminating implantable cardioverter-defibrillator shocks, and sudde

138 comparable to rates observed in transvenous implantable cardioverter-defibrillator studies.

139 ients who had a legacy pacemaker or a legacy implantable cardioverter-defibrillator system.

140 predicted to have an attenuated benefit from implantable cardioverter-defibrillator therapy (older ad

141 his disease, it is also well recognized that implantable cardioverter-defibrillator therapy is associ

142 n remains challenging because the benefit of implantable cardioverter-defibrillator therapy may not b

143 Appropriate implantable cardioverter-defibrillator therapy was deliv

144 t benefit from additional primary prevention implantable cardioverter-defibrillator therapy, as oppos

145 eart failure, and 6 (23%) were suggested for implantable cardioverter-defibrillator therapy.

146 hy patients evaluated for primary prevention implantable cardioverter-defibrillator therapy.

147 Implantable cardioverter-defibrillator therapy.

148 nts with a clinical diagnosis of CPVT and an implantable cardioverter-defibrillator underwent a basel

149 w incidence of SCD and a low rate of primary implantable cardioverter-defibrillator utilization in pa

150 pite a low rate (4.0%) of primary prevention implantable cardioverter-defibrillator utilization.

151 therapy with defibrillator (CRT-D; CRT with implantable cardioverter-defibrillator) was associated w

152 A total of 81 patients received an implantable cardioverter-defibrillator, 34 were successf

153 s, kidney disease, cardiac resynchronization implantable cardioverter-defibrillator, and VT storm des

154 23 patients (29%) of 78 IVF patients with an implantable cardioverter-defibrillator, with a median of

155 erent implant techniques of the subcutaneous implantable cardioverter-defibrillator.

156 isk is sufficient to justify placement of an implantable cardioverter-defibrillator.

157 med in 1,612 hospitals); 2) ICD Registry for implantable cardioverter-defibrillators (158,649 procedu

158 Antitachycardia pacing (ATP) in implantable cardioverter-defibrillators (ICD) decreases

159 Older recipients of implantable cardioverter-defibrillators (ICDs) are at in

160 Although implantable cardioverter-defibrillators (ICDs) are frequ

161 ted risk for sudden cardiac death (SCD), and implantable cardioverter-defibrillators (ICDs) are the m

162 The effectiveness of implantable cardioverter-defibrillators (ICDs) for prima

163 Clinical trials of implantable cardioverter-defibrillators (ICDs) for secon

164 Implantable cardioverter-defibrillators (ICDs) have a ro

165 The programming of implantable cardioverter-defibrillators (ICDs) influence

166 risk of atrial fibrillation in patients with implantable cardioverter-defibrillators (ICDs), but vent

167 ufacturer-specific, strategic programming of implantable cardioverter-defibrillators (ICDs), includin

168 influence outcomes among patients receiving implantable cardioverter-defibrillators (ICDs).

169 s, 44 patients received secondary prevention implantable cardioverter-defibrillators (long QT syndrom

170 Transvenous implantable cardioverter-defibrillators (TV-ICDs) improv

171 , beta-blockers alone in 350 (58%) patients, implantable cardioverter-defibrillators alone in 25 (4%)

172 Implantable cardioverter-defibrillators are indicated fo

173 patients with dilated cardiomyopathy (DCM), implantable cardioverter-defibrillators do not increase

174 ation of at-risk patients and utilization of implantable cardioverter-defibrillators for prevention o

175 ion of high-risk patients who benefited from implantable cardioverter-defibrillators for sudden death

176 ODS AND Patients implanted with subcutaneous implantable cardioverter-defibrillators from 2 hospitals

177 retrospective cohort study of patients with implantable cardioverter-defibrillators identified from

178 Implantable cardioverter-defibrillators were placed in 5

179 In patients with implantable cardioverter-defibrillators, healthcare util

180 Device therapy, primarily with implantable cardioverter-defibrillators, is often recomm

181 The implantable-cardioverter defibrillator (ICD) lead is the

182 A fully-implantable CI (FICI) would address these issues.

183 igh risk for stroke with a previously placed implantable CIED, but without a prior diagnosis of clini

184 serve as a middle-ear microphone for totally implantable cochlear- or middle-ear hearing aids.

185 neal angle changes produced after 2 years of implantable collamer lens (ICL) V4c (STAAR Surgical AG,

186 The implantable components integrated in the brain-spine int

187 at are vascularized, autologous, functional, implantable, cost-effective, and ethically feasible.

188 1), PV (n = 29), or ICED (n = 30) (automatic implantable defibrillator [n = 11] or pacemaker [n = 19]

189 000, through October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter de

190 icant ventricular arrhythmia, indication for implantable defibrillator, or new or worsening HF at 6-m

191 Among patients with implantable defibrillators (ICD), use of remote patient

192 Patients at risk currently receive implantable defibrillators that deliver electrical shock

193 story and disease course for many, including implantable defibrillators, heart transplant, external d

194 ieve primary prevention of sudden death with implantable defibrillators.

195 g step towards an applicable biosensor in an implantable device able to quantify VEGF reliably after

196 (Respicardia Inc, Minnetonka, MN, USA) is an implantable device which transvenously stimulates a nerv

197 cules is a central paradigm in the design of implantable devices and biosensors with improved clinica

198 f multiple biomarkers for cancer diagnostic, implantable devices for in vivo sensing and, development

199 Implantable devices have a large potential to improve hu

200 Implantable devices offer an alternative to systemic del

201 l antimicrobial agents from various metallic implantable devices or prostheses to effectively decreas

202 rovide new opportunities for next-generation implantable devices owing to their soft mechanical natur

203 a basis for the next generation of wireless implantable devices.

204 ons where high density is needed, such as in implantable devices.

205 ry and eventually the development of totally implantable devices.

206 em promising power sources for the future of implantable devices.

207 are attractive for flexible electronics and implantable devices.

208 with biological systems in both wearable and implantable devices.

209 The implantable drug-delivery system can be powered with a T

210 tric-nanogenerator (TENG)-based self-powered implantable drug-delivery system is presented.

211 icant step forward toward the development of implantable drug-delivery systems.

212 ant progress toward the realization of ideal implantable electrical probes allowing for mapping and t

213 Implantable electrical probes have led to advances in ne

214 Most cardiovascular implantable electronic device (CIED) recipients are elde

215 Cardiovascular implantable electronic device (CIED) removal and interro

216 The presence of a cardiovascular implantable electronic device has long been a contraindi

217 is a serious complication of cardiovascular-implantable electronic device implantation and necessita

218 we identified patients with de novo cardiac implantable electronic device implantations between Janu

219 tively enrolled subjects with cardiovascular-implantable electronic device infections at multiple ins

220 Management guidelines for cardiac implantable electronic device infections exist, but prac

221 Overall, 434 patients with cardiovascular-implantable electronic device infections were prospectiv

222 The potential for cardiac implantable electronic device leads to interfere with tr

223 y 4 of them were managed with cardiovascular-implantable electronic device removal and reimplantation

224 trategy of continued warfarin during cardiac implantable electronic device surgery was safe and reduc

225 pitalization within 1 year following cardiac implantable electronic device surgery.

226 The use of cardiac implantable electronic devices (CIED) is increasing, and

227 Cardiac implantable electronic devices (CIEDs) have been among t

228 Because of the increasing use of cardiac implantable electronic devices (CIEDs), it is important

229 plored its consequences using cardiovascular implantable electronic devices (CIEDs).

230 The future of cardiac implantable electronic devices includes pacing and perha

231 ss the skin barrier is a key requirement for implantable electronic devices.

232 tant aspect of care in patients with cardiac implantable electronic devices; however, relatively litt

233 hese types of electronics (e.g., wearable or implantable electronics, sensors for soft robotics, e-sk

234 mechanical energy to drive portable/wearable/implantable electronics.

235 en mainly employed as a protective layer for implantable electronics.

236 n freely behaving mice, we developed a fully implantable, flexible, wirelessly powered optoelectronic

237 he main obstacle in realization of a totally implantable hearing aid is a lack of reliable implantabl

238 These compact, fully implantable heart pumps are capable of providing meaning

239 Implantable hemodynamic monitor-derived baseline ePAD an

240 pose of this analysis was to examine whether implantable hemodynamic monitor-derived baseline estimat

241 "Next-generation" implantable hemodynamic monitors are in development, and

242 Early studies using implantable hemodynamic monitors demonstrated the potent

243 These data demonstrate that general use of implantable hemodynamic technology in a nontrial setting

244 l tissue constructs using biomaterials as an implantable hiPSC-derived myocardium provides a path to

245 data capitalize on the unique ability of an implantable iontophoretic device to deliver much higher

246 We have fabricated implantable iontophoretic devices and tested the local i

247 Here we show implantable light-delivery devices made of bio-derived o

248 eeds, we propose the Biocage, a customizable implantable local drug delivery platform.

249 recurrent syncope and asystole documented by implantable loop recorder.

250 vasovagal syncope and asystole documented by implantable loop recorder.

251 igate if such signals could be recorded with implantable means and used to derive BP markers.

252 anic substrates in human blood and urine for implantable medical devices (IMDs) was investigated.

253 ld applications such as wireless powering of implantable medical devices and wireless charging of sta

254 oal for those engaged in research to develop implantable medical devices is to develop mechatronic im

255 biofilm formation is a major complication of implantable medical devices that results in therapeutica

256 ggests the utility of l-DOPA in the field of implantable medical devices, such as biosensors, as well

257 Infection is a major complication of implantable medical devices, which provide a scaffold fo

258 applications, from robotics to perhaps even implantable medical devices.

259 eliver albumin directly into tumors using an implantable microdevice, which was adapted and modified

260 eliver albumin directly into tumors using an implantable microdevice, which was adapted and modified

261 e described a low cost silicon based 16-site implantable microelectrode array (MEA) chip fabricated b

262 ntegrated microscopes in conjunction with an implantable microendoscopic lens to guide light into and

263 mplantable hearing aid is a lack of reliable implantable microphone.

264 erior segment of mouse and rabbit eyes using implantable microsensors.

265 addressable, multicolor mu-ILEDs with fully implantable, miniaturized platforms.

266 precedented opportunities to deploy advanced implantable monitoring systems that eliminate risks, cos

267 egies, and in vivo demonstrations in rats of implantable, multifunctional silicon sensors for the bra

268 asis for the rational design of wearable and implantable nanodevices in biosensing and thermotherapic

269 n data obtained over several years using the implantable NeuroVista seizure advisory system.

270 However, a soft form of the implantable optoelectronic device for optical sensing an

271 rray is applied as a human eye-inspired soft implantable optoelectronic device that can detect optica

272 incretin-based therapies include a miniature implantable osmotic pump to give continuous delivery of

273 hospitalization risk reduction with a novel implantable PA pressure monitoring system (CardioMEMS HF

274 study describes a method using programmable, implantable peristaltic pumps to chronically deliver dru

275 Thus, implantable, peristaltic pumps provide a number of benef

276 us, we demonstrate the facile fabrication of implantable porous HEALs that support liver stage human

277 er in patients managed with guidance from an implantable pulmonary artery pressure sensor compared wi

278 site pain, subcutaneous displacement of the implantable pulse generator, transient oscillopsia and m

279 patibility and long-term biostability of the implantable PV is ensured through the use of an hermetic

280 l zinc (Zn) is a promising new generation of implantable scaffold for cardiovascular and orthopedic a

281 s current and future applications of "smart" implantable scaffolds capable of controlling the cascade

282 ource indicated the probability of realizing implantable self-powered autonomously operated artificia

283 A significant problem with implantable sensors is electrode fouling, which has been

284 ration implant materials such as pacemakers, implantable sensors, or prosthetic devices in hybrids of

285 sh by describing a future trend for in vivo, implantable sensors, which aims to build on current prog

286 In the work presented here, a subcutaneously implantable silicon PV cell, operated in conjunction wit

287 We demonstrate an implantable silicon-based probe with a compact light del

288 nge of non-invasive, minimally invasive, and implantable systems to address challenges in biomedicine

289 BPnP amplitude could serve as a BP marker in implantable systems.

290 ificantly degrade the long-term stability of implantable systems.

291 in response to dobutamine as measured using implantable telemetry devices.

292 creates a range of opportunities, including implantable therapeutic devices with automated feedback,

293 This work opens a new field of implantable therapeutic devices-oculomotor prosthetics-d

294 n of the thromboresistance of cardiovascular implantable therapeutic devices.

295 an alternative platform, which we call iTAG (implantable thermally actuated gel), where an implanted

296 ction and assembly of functional tissues and implantable tissue grafts.

297 Here we show that an implantable vagus nerve-stimulating device in epilepsy p

298 linical registry to monitor the safety of an implantable vascular-closure device that had a suspected

299 ential safety signals among recipients of an implantable vascular-closure device, with initial alerts

300 e describe a minimally invasive, permanently implantable window for high-resolution intravital imagin